New screening strategy could speed diagnosis of inherited aldosteronism

NCT ID NCT07700888

First seen Jul 14, 2026 · Last updated Jul 15, 2026 · Updated 1 time

Summary

This study tests a new screening method to tell apart two causes of high blood pressure: a rare genetic condition called Glucocorticoid-Remediable Aldosteronism (GRA) and a more common adrenal tumor. The approach combines an overnight dexamethasone suppression test with detailed steroid measurements. Researchers aim to find clear cut-off points that could help doctors identify GRA without needing genetic testing first.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
1 mg overnight dexamethasone suppression test
What this could lead to
If successful, this screening strategy could provide a faster, cheaper way to identify Glucocorticoid-Remediable Aldosteronism, reducing the need for genetic testing in many patients.
What could go wrong
This is a small observational study, so the diagnostic cut-off points may not generalize to broader populations. The test may not perfectly distinguish all cases.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GLUCOCORTICOID-REMEDIABLE ALDOSTERONISM are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Peking Union Medical Colledge Hospital

    Beijing, 李泽文, 456350, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.